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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.06.029Background: New-onset atrial fibrillation after coronary artery bypass grafting is
common. Medical therapy includes various antiarrhythmic drugs to control heart
rate and restore sinus rhythm. The purpose of this study was to determine the
duration of antiarrhythmic therapy after discharge from the hospital.
Methods: One hundred twenty-nine patients in whom new atrial fibrillation after
coronary artery bypass grafting developed and successfully reverted to sinus rhythm
were prospectively randomized at dismissal to receive antiarrhythmic therapy for 1
week (group A; n  44), 3 weeks (group B; n  42), or 6 weeks (group C; n  43).
Patients were followed up for an additional 4 weeks after discontinuation of
antiarrhythmic therapy for detection of recurrent atrial fibrillation.
Results: The incidence of new atrial fibrillation during the study period was 21.2%
(256/1206). Among the 129 patients who consented to the study, conversion to sinus
rhythm was accomplished with the following medications: amiodarone (group A,
82%; group B, 93%; group C, 88%; P .29), digoxin (group A, 16%; group B, 7%;
group C, 7%; P  .29), -blockers (group A, 27%; group B, 19%; group C, 14%;
P  .30), calcium channel blockers (group A, 2%; group B, 2%; group C, 0%; P 
.60), quinidine (group A, 2%; group B, 2%; group C, 7%; P  .44), and procain-
amide (group A, 4.5%; group B, 2%; group C, 0%; P  .37). Follow-up was
completed in 128 patients (99.2%). There was no significant difference in the
recurrence of atrial fibrillation among groups (0%, 2%, and 0% for groups A, B, and
C, respectively).
Conclusions: Patients with new atrial fibrillation after coronary artery bypass
grafting, converted to normal sinus rhythm before hospital discharge, have a benign
course. Antiarrhythmic therapy as short as 1 week may be appropriate in these patients.
New-onset atrial fibrillation (AF) after coronary artery bypass graft-ing (CABG) is common, with an incidence of up to one third ofpatients.1-3 Although postoperative atrial tachyarrhythmia is oftenregarded as a temporary problem related to the operation andtherefore innocuous, this complication has clinically significantadverse effects on patient outcome. Post-CABG atrial arrhythmia
is associated with a twofold increase in the duration of intensive care unit stay and
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CSPa 50% to 70% prolongation of total hospitalization time
with attendant increased hospitalization costs, and it is an
important risk factor for perioperative cerebrovascular ac-
cidents.4,5
Medical therapy includes various drugs, such as
-blockers, calcium channel blockers, digoxin, sotalol,
amiodarone, quinidine, ibutilide, and procainamide,
among others, to control heart rate and restore sinus
rhythm.3 When postoperative AF is successfully con-
verted to sinus rhythm, it is unlikely to recur, and nearly
all of these patients are discharged from the hospital in
sinus rhythm.1 Most of the antiarrhythmic agents have
significant cardiac and noncardiac adverse effects.6 It is
not clear how soon these patients may discontinue anti-
arrhythmic therapy to avoid these side effects without
risking recurrence of AF. Current recommendations of
the American Heart Association and the American Col-
lege of Cardiology for the management of postoperative
AF do not address the duration of antiarrhythmic thera-
py.7 We hypothesized that the course of antiarrhythmic
therapy after CABG should be short and that there should
be no difference in the recurrence of AF among groups of
patients treated for different times. Therefore, we con-
ducted this prospective randomized study among patients
undergoing CABG in whom new-onset postoperative AF
developed.
Methods
Patient Selection
From September 1, 1999, to May 31, 2003, 1206 patients under-
went CABG at the Hadassah University Hospital, Jerusalem. We
prospectively collected preoperative and postoperative clinical
data on these patients. Inclusion criteria for participation in this
study were (1) new-onset AF after CABG, (2) no history of atrial
or ventricular arrhythmia, (3) no previous use of antiarrhythmic
therapy, (4) normal sinus rhythm controlled with antiarrhythmic
therapy by the time of hospital discharge, and (5) informed consent
Figure 1. Study population. AF, Atrial fibrillation; CABG, coronary
artery bypass grafting.from each participant. Patients were excluded if they had a history
402 The Journal of Thoracic and Cardiovascular Surgery ● Febrof chronic or paroxysmal AF, if they took antiarrhythmic drugs
before surgery, or if they were discharged with AF. Fifteen pa-
tients died after surgery and were excluded from the statistical
analysis. AF developed in 256 patients (21.2%) after surgery. In
only 5 patients was sinus rhythm not restored, and they were
discharged with AF. The success rate of drugs (247 patients) or
electrical conversion (4 patients) was 98% (251/256). Fifty-nine
patients (23%) were excluded because they had a history of AF (37
patients), received antiarrhythmic therapy before surgery (18 pa-
tients), or were discharged with AF (5 patients). One hundred
ninety-seven patients were eligible to participate in the study.
Sixty-eight patients who fulfilled the inclusion criteria refused to
participate in the study. The remaining 129 patients were random-
ized according to the study protocol (Figure 1), which was ap-
proved by the institutional review board.
Study Protocol
One hundred twenty-nine patients were included in the study.
All patients were discharged with antiarrhythmic therapy to
maintain sinus rhythm. On the day of discharge, patients were
randomized into 1 of 3 therapy groups to receive antiarrhythmic
therapy for 1 week (group A; 44 patients), 3 weeks (group B; 42
patients), or 6 weeks (group C; 43 patients). Patients who
fulfilled the inclusion criteria but refused randomization to the
study were discharged from the hospital with antiarrhythmic
therapy for 6 weeks according to our nonstudy protocol. At the
end of each study period (1, 3, or 6 weeks), patients discontin-
ued the antiarrhythmic therapy and underwent a 12-lead elec-
trocardiogram (ECG) for rhythm documentation. All patients
were followed up during their group time (1, 3, or 6 weeks) and
an additional 4 weeks for recurrence of significant arrhythmia
or readmission for any reason. At the end of this 4-week period,
patients were requested to obtain a second 12-lead ECG. All
ECGs and postoperative clinical data were prospectively col-
lected. One (group C) patient was lost to follow-up and was
excluded from the final analysis.
Patients who received preoperative -blockers, providing
that these drugs were not prescribed as an antiarrhythmic ther-
apy, were included in the study, and there was no statistical
difference in the number of these patients among the 3 groups
(group A, 56.8%; group B, 59.5%; group C, 62.7%). Patients
continued to receive -blockers after surgery as well. If post-
operative AF occurred, they were treated with additional anti-
arrhythmic drugs. When these patients were included in the
study, they were discharged with -blockers plus the additional
antiarrhythmic therapy. By the end of the randomized study
duration (1, 3, or 6 weeks), they discontinued only the addi-
tional antiarrhythmic drug.
Operative Technique
All operations were performed through a median sternotomy. A
standard cardiopulmonary bypass technique was instituted in 106
(82%) patients (35 in group A, 37 in group B, and 34 in group C;
P  .46) by using aortoatrial cannulation with a roller pump at
moderate hypothermia (28°C-32°C). Myocardial protection was
based on intermittent antegrade and retrograde tepid blood cardio-
plegia. Distal anastomoses were performed during a single period
of aortic crossclamping, and proximal anastomoses were per-
uary 2005
Izhar et al Cardiopulmonary Support and Physiology
CS
Pformed with partial aortic clamping during rewarming. Conduits
for bypass included internal thoracic and radial arteries and saphe-
nous veins. Twenty-three patients (9 in group A, 5 in group B, and
9 in group C; P  .6) underwent CABG with an off-pump
technique (surgeon’s preference).
Management of Postoperative AF
Patients did not receive prophylactic antiarrhythmic therapy during
the preoperative or postoperative period. Management of postop-
erative AF consisted of (1) immediate heart rate control by intra-
venous calcium channel blockers; (2) conversion to sinus rhythm
by using an intravenous loading dose of amiodarone (5-7 mg/kg
over 30-60 minutes, then 1 g/24 h followed by oral maintenance
[200 mg daily]); (3) using alternative antiarrhythmic therapy (-
blockers, calcium channel blockers, digoxin, quinidine, and pro-
cainamide) for patients who were not responsive to amiodarone or
had contraindications to its use (bradycardia or atrioventricular
block); (4) direct current cardioversion for hemodynamically un-
stable patients or patients who were not responding to medical
therapy; and (5) anticoagulation with intravenous heparin (moni-
tored by partial thromboplastin time twice laboratory control val-
ues or higher) for patients who were not converted to sinus rhythm
within 48 hours. Patients in whom sinus rhythm was restored were
discharged without anticoagulation. All patients received daily
aspirin 100 mg for life.
Follow-up
A closed follow-up was designed for the patients included in this
study. (1) They were telephoned during the time they were ran-
domized (1, 3, or 6 weeks) for confirmation that they were taking
the antiarrhythmic therapy. (2) They received a second call by the
day they discontinued therapy for confirmation that ECG recording
would be obtained. (3) They received a third call after an addi-
TABLE 1. Patient characteristics
Variable
Group A
(1 wk; n  44)
Age (y) 66.80 8.73*
Male sex 39 (89)
Smoking 24 (54.5)
Diabetes mellitus 16 (36)
Hypertension 27 (61)
Hypercholesterolemia 29 (66)
Renal failure 1 (2)
History of CVA 3 (7)
Previous MI 19 (43)
Previous PCI 13 (29.5)
Three-vessel disease 34 (77)
EF 50% 10 (22.5)
Urgent operation 21 (48)
Use of CPB 35 (79.5)
No. distal anastomoses 2.50 0.79
Length of stay (d) 9.05 2.63
*Data are mean  SD or n (%). CPB, Cardiopulmonary bypass; CVA, c
percutaneous coronary intervention.tional 4 weeks for confirmation that a second ECG would be
The Journal of Thoraciobtained. (4) They participated in an outpatient visit by the end of
the follow-up period. (5) They were asked to inform us about any
readmission or emergency department visits during the duration of
the study. All medical records of readmission were collected. (6) A
letter covering all the study details was sent to all family physi-
cians caring for these patients.
Statistical Analysis
Data are expressed as absolute numbers or percentages and,
where appropriate, as mean  SD. Continuous variables were
compared between groups by means of 1-way analysis of vari-
ance. Categorical variables were compared by means of 2 or
Fisher exact tests.
Results
Demographics
The mean age of the patients randomized to the study was
68.8  8.7 years, 64.9  9.6 years, and 67.5  8.3 years in
groups A, B, and C, respectively (P  .37). The patients’
demographics and preoperative variables are presented in
Table 1. There were no statistically significant differences
among groups.
Postoperative AF
The incidence of new-onset postoperative AF was 21.2% (256/
1206). The various antiarrhythmic drugs used among the 3
groups of patients are listed in Table 2. Most patients were
converted to sinus rhythm with amiodarone (group A, 82%;
group B, 93%; group C, 88%; P  .29). Other medications
used to control AF included digoxin (group A, 16%; group B,
7%; group C, 7%; P .29), -blockers (group A, 27%; group
Group B
wk; n  42)
Group C
(6 wk; n  43) P value
4.90 9.64 67.56 8.38 .37
38 (90.5) 37 (86) .82
17 (40.5) 21 (49) .42
11 (26) 16 (37) .49
25 (59.5) 28 (65) .86
27 (64) 24 (56) .58
1 (2) 4 (9) .21
2 (5) 8 (19) .072
18 (43) 21 (49) .82
8 (19) 6 (14) .19
37 (88) 31 (72) .45
8 (19) 10 (23) .73
19 (45) 24 (56) .69
37 (88) 34 (79) .46
2.88 0.97 2.77 1.00 .15
8.98 2.46 9.30 2.55 .85
vascular accident; EF, ejection fraction; MI, myocardial infarction; PCI,(3
6
erebroB, 19%; group C, 14%; P  .30), calcium channel blockers
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CSP(group A, 2%; group B, 2%; group C, 0%; P .60), quinidine
(group A, 2%; group B, 2%; group C, 7%; P  .44), and
procainamide (group A, 4.5%; group B, 2%; group C, 0%; P
 .37). Direct current cardioversion was required in a small
number of patients (group A, 2%; group B, 2%; group C, 5%;
P  .77).
AF-related complications included low cardiac output
(group A, 0%; group B, 4%; group C, 0%; P  .10) and
requirement for anticoagulation therapy (group A, 21%;
group B, 17%; group C, 12%; P .54). None of the patients
had stroke.
Follow-up and Recurrence of AF
All patients were followed up for 4 weeks after discontin-
uation of medical therapy. Follow-up was completed in 128
patients (99.2%): group A, 100%; group B, 100%; and
group C, 98% (P  .82).
Recurrence of AF during the follow-up period was 0% in
group A, 2% in group B, and 0% in group C (P .38). Only
1 patient in group B was readmitted for recurrent asymp-
tomatic AF 1 week after he discontinued the treatment with
amiodarone. He was successfully converted to sinus rhythm
after resuming amiodarone therapy for another 4 weeks.
None of the patients had stroke or episodes of transient
ischemic attack during the follow-up period.
Eight patients were readmitted for various reasons: pneu-
monia, 1 patient; congestive heart failure, 2 patients; pleural
effusion, 2 patients; and chest pain, arm wound infection,
and AF, 1 patient each (group A, 4.8%; group B, 9.5%;
group C, 5%; P  .62).
Discussion
Atrial tachyarrhythmias may occur in 25% to 40% of pa-
tients undergoing CABG, with a peak incidence between
the second and fourth days after surgery. Among the pa-
tients who have no history of atrial tachyarrhythmias, spon-
taneous conversion of AF has been reported in 15% to 30%
within 2 hours.8,9
The precise cause and mechanism of the development of
postoperative AF has yet to be established. It involves
TABLE 2. Antiarrhythmic therapy for postoperative atrial fi
Therapy
Group A
(1 wk; n  44)
Amiodarone 36 (82)
-Blockers 12 (27)
Digoxin 7 (16)
Calcium channel blockers 1 (2)
Quinidine 1 (2)
Procainamide 2 (4.5)
Data are n (%).reentry, resulting from dissimilar refractoriness between
404 The Journal of Thoracic and Cardiovascular Surgery ● Febradjacent atrial areas, without a known reason.10 Risk factors
associated with the development of postoperative AF in-
clude advanced age, prolonged preoperative atrial conduc-
tion, atrial myolysis, chronic obstructive pulmonary disease,
excess circulating catecholamines, electrolyte imbalance,
atrial myocardial ischemia, -blocker withdrawal, pro-
longed aortic crossclamping time, and right atrial manipu-
lations.1-3
The principles of treatment for new-onset postopera-
tive AF are similar to those for atrial tachyarrhythmias in
other clinical circumstances.11 Mainly, 2 management
strategies are available to treat patients with persistent
AF: rate control and rhythm control.12 Although the
rate-control strategy is preferred for patients in whom
restoration of sinus rhythm is less important, most pa-
tients with new-onset postoperative AF are treated with
antiarrhythmic therapy.13 A recent prospective random-
ized study comparing primary rate control with conver-
sion strategy in postoperative AF showed little difference
in time to conversion between the 2 groups of patients.9
This study also did not show a statistically significant
reduction in the total length of stay through the conver-
sion strategy, although the time from operation to dis-
charge was significantly decreased.9 The control of ven-
tricular rate, conversion to sinus rhythm, maintenance of
regular rhythm, and anticoagulation to protect against
thromboembolic complications are the goals of therapy.11
When should we discontinue antiarrhythmic therapy in
patients undergoing CABG in whom new-onset postopera-
tive AF develops? The treatment of patients with postoper-
ative AF has not been standardized despite large clinical
experience and research.14 There are few data regarding the
post–hospital discharge course of patients with this compli-
cation.15,16 It is generally believed that there is no need for
long-term suppressive therapy because in patients without a
history of atrial tachyarrhythmia, once AF is converted to
sinus rhythm, it is unlikely to recur.6 However, one of the
fundamental questions regarding antiarrhythmic therapy for
postoperative AF is whether any therapy should be given at
ation
Group B
(3 wk; n  42)
Group C
(6 wk; n  43) P value
39 (93) 38 (88) .29
8 (19) 6 (14) .30
3 (7) 3 (7) .29
1 (2) 0 .60
1 (2) 3 (7) .44
1 (2) 0 .37brillall, once patients are discharged home already in sinus
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Prhythm. We searched the medical literature for guidelines or
studies addressing no additional antiarrhythmic therapy at
discharge, but we could not find this practice as evidence
based. We have demonstrated in this study that the duration
of antiarrhythmic therapy in these patients may be very
short, from 1 to 3 weeks, no matter what antiarrhythmic
drugs have been used. There was no significant difference in
the recurrence of AF during the follow-up period among the
different therapy groups.
Our results are consistent with the very few studies
reporting the frequency of recurrent AF after reversion or
conversion to sinus rhythm after surgery. Kowey and asso-
ciates15 recently reported a retrospective analysis of the
intermediate prognosis of patients undergoing CABG who
had been treated with different strategies for postoperative
AF. They concluded that the rate of recurrence of AF after
discharge was similar in patients receiving class I or class
III antiarrhythmic drugs together with rate-control agents
and in those receiving rate-control drugs alone. Landymore
and Howell16 reported on the recurrence of postoperative
atrial arrhythmia in patients who had been treated with
digoxin for 3 to 8 weeks after CABG. Their data indicated
that AF rarely recurred after hospital discharge and was
never symptomatic. They concluded that patients in whom
new-onset postoperative AF developed should be treated
with digoxin for 3 weeks after operation and that drug
therapy should then be discontinued indefinitely. Yilmaz
and associates17 have found that placebo was comparable to
any medication in preventing the recurrence of AF after
CABG: the relapse rate within 90 days of operation was 1 of
30 taking placebo, 2 of 30 taking quinidine, 2 of 30 taking
verapamil, and 2 of 30 taking amiodarone.
Most of the patients in our study were successfully
treated with amiodarone to control AF and maintain sinus
rhythm in the postoperative period. Amiodarone, a class III
antiarrhythmic agent, increases the refractory period of
atrial and ventricular muscle as well as the atrioventricular
node. In addition, it has mild -blocker and calcium channel
blocker activity. It has been reported that the drug is mod-
erately effective for pharmacologic cardioversion of recent-
onset AF.18 The conversion rate in patients with AF longer
than 7 days is limited. Amiodarone also has been proven
effective for conversion of persistent AF.19 A meta-analysis
of 91 trials not specifically related to surgery concluded that
the relative efficacy of the most commonly used antiarrhyth-
mic drugs seems similar.20 Class IA (quinidine, procain-
amide, and disopyramide), class IC (flecainide and
propafenone), and class III (amiodarone, sotalol, ibutilide,
and dofetilide) drugs were all more effective than placebo,
converting 40% to 60% of the patients compared with 30%
with placebo. Comparisons of class IA or class IC with class
III drugs revealed no significant differences. In deciding the
nature and duration of drug therapy for postoperative AF,
The Journal of Thoraciwe should consider not only the efficacy of the various
antiarrhythmic drugs, but also their undesirable effects.
Many previous studies have addressed the increased risk for
proarrhythmias—specifically ventricular tachycardia and
ventricular fibrillation—when using class I drugs to prevent
recurrence of AF.6 Among the other serious side effects of
this class of drugs are allergic/immune reactions (lupus-like
syndrome), thrombocytopenia, myocardial depression, and
gastrointestinal disturbance. Amiodarone, a class III antiar-
rhythmic drug, has been reported to be effective in prevent-
ing and treating postoperative AF.21,22 The dose regimen
used in our patients did not result in important side effects,
and no-drug related complications were reported during the
follow-up period. The half-life of amiodarone is prolonged,
ranging from 26 to 107 days.23 Therefore, it is likely that
once the patient with postoperative AF is loaded with ami-
odarone and converted to sinus rhythm, he or she may gain
its persistent antiarrhythmic effect for several weeks.22,23
This strengthens our conclusion that the antiarrhythmic
therapy after postoperative AF should be brief.
Twenty-four patients from the study population were
operated on with the off-pump technique. Recent data indi-
cate that these patients have a similar or lower incidence of
postoperative AF than patients with the on-pump tech-
nique.24-26 Our incidence of postoperative AF for both
groups was not statistically different. Therefore, the off-
pump patients who met the criteria of this study were
eligible to be included in this trial, and both groups were
analyzed together.
Limitations of the Study
Holter monitoring was not performed to screen for postop-
erative AF or other arrhythmia during the postoperative
follow-up period. Instead, patients were asked to obtain a
12-lead ECG at the day therapy was discontinued and 4
weeks later. All readmission records were also evaluated for
recurrent arrhythmia. The primary goal of the study was to
determine when to discontinue the antiarrhythmic therapy
for postoperative AF. We believe that failure to detect brief
asymptomatic episodes of AF is unlikely to affect patient
care or affect it adversely and that this does not detract from
the clinical implication of this study.
Conclusions
Postoperative atrial arrhythmia remains a vexing clinical
problem, the therapy of which has not yet been standard-
ized. We conclude from our prospective randomized study
that antiarrhythmic therapy for postoperative AF in patients
undergoing CABG should be brief. A 1- to 3-week period is
safe and sufficient in most patients.
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